MedTrace Logo

Effect of Bifidobacterium on Irritable Bowel Syndrome

NCT00737841 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2008-08-20

No results posted yet for this study

Summary

There has been no data on effect of Bifidobacterium breve on symptoms of patients with irritable bowel syndrome (IBS). We hypothesized that Bifidobacterium breve is effective on symptoms of IBS patients.

Conditions

  • Irritable Bowel Syndrome

Interventions

DRUG

Bifidobacterium breve

1.0 g of Bifidobacterium breve, taking orally, 3 times a day for 8 weeks.

DRUG

Placebo

1.0 g of placebo, taking orally, 3 times a day for 8 weeks.

Sponsors & Collaborators

  • Tohoku University

    lead OTHER

Principal Investigators

  • Shin Fukudo, MD, PhD · Tohoku University

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2008-08-31
Completion
2008-09-30

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00737841 on ClinicalTrials.gov